Trial Profile

A phase II, double-blind, randomised placebo-controlled trial of EpiCept NP-1 topical cream in patients with chemotherapy-induced peripheral neuropathy.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Feb 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amitriptyline/ketamine (Primary)
Indications Neuropathic pain
Focus Therapeutic Use
Sponsors Immune Pharmaceuticals Inc

Most Recent Events

07 Feb 2011 Positive preliminary results reported in an EpiCept media release.
07 Feb 2011 Primary endpoint 'Pain-intensity' has been met, as reported in an EpiCept media release.
11 Nov 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com